Werewolf Therapeutics Inc (HOWL) - Net Assets
Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) has net assets worth $16.29 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($24.16 Million) and total liabilities ($7.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Werewolf Therapeutics Inc (HOWL) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.29 Million |
| % of Total Assets | 67.45% |
| Annual Growth Rate | 16.8% |
| 5-Year Change | -83.76% |
| 10-Year Change | N/A |
| Growth Volatility | 310.23 |
Werewolf Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Werewolf Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Werewolf Therapeutics Inc stock valuation.
Annual Net Assets for Werewolf Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Werewolf Therapeutics Inc from 2019 to 2025. Also explore Werewolf Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $24.80 Million | -66.20% |
| 2024-12-31 | $73.39 Million | -34.10% |
| 2023-12-31 | $111.37 Million | -8.96% |
| 2022-12-31 | $122.34 Million | -19.93% |
| 2021-12-31 | $152.79 Million | +71.25% |
| 2020-12-31 | $89.22 Million | +813.29% |
| 2019-12-31 | $9.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Werewolf Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45100200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.02% |
| Other Components | $500.21 Million | 2016.57% |
| Total Equity | $24.80 Million | 100.00% |
Werewolf Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Werewolf Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Toro Energy Ltd
AU:TOE
|
$46.81 Million |
|
INFOvine co. Ltd
KQ:115310
|
$46.84 Million |
|
Beyaz Filo Oto Kiralama AS
IS:BEYAZ
|
$46.84 Million |
|
Simula Technology
TWO:3511
|
$46.86 Million |
|
Annovis Bio Inc
NYSE:ANVS
|
$46.80 Million |
|
Ram-On Investments and Holdings Ltd
TA:RMN
|
$46.79 Million |
|
Live Verdure Ltd
AU:LV1
|
$46.79 Million |
|
Alpha Holdings Inc
KQ:117670
|
$46.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Werewolf Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 73,390,000 to 24,805,000, a change of -48,585,000 (-66.2%).
- Net loss of 60,822,000 reduced equity.
- New share issuances of 5,939,000 increased equity.
- Other factors increased equity by 6,298,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.82 Million | -245.2% |
| Share Issuances | $5.94 Million | +23.94% |
| Other Changes | $6.30 Million | +25.39% |
| Total Change | $- | -66.20% |
Book Value vs Market Value Analysis
This analysis compares Werewolf Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.83x to 1.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.34 | $0.96 | x |
| 2020-12-31 | $3.11 | $0.96 | x |
| 2021-12-31 | $8.28 | $0.96 | x |
| 2022-12-31 | $4.24 | $0.96 | x |
| 2023-12-31 | $3.12 | $0.96 | x |
| 2024-12-31 | $1.67 | $0.96 | x |
| 2025-12-31 | $0.53 | $0.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Werewolf Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -245.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.80x
- Recent ROE (-245.20%) is below the historical average (-82.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -112.50% | 0.00% | 0.00x | 2.22x | $-11.97 Million |
| 2020 | -16.74% | 0.00% | 0.00x | 1.08x | $-23.86 Million |
| 2021 | -32.57% | -1199.78% | 0.02x | 1.17x | $-65.05 Million |
| 2022 | -42.15% | -314.40% | 0.10x | 1.31x | $-63.80 Million |
| 2023 | -33.55% | -187.37% | 0.11x | 1.57x | $-48.51 Million |
| 2024 | -96.08% | -3740.85% | 0.01x | 1.73x | $-77.85 Million |
| 2025 | -245.20% | 0.00% | 0.00x | 2.80x | $-63.30 Million |
Industry Comparison
This section compares Werewolf Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Werewolf Therapeutics Inc (HOWL) | $16.29 Million | -112.50% | 0.48x | $46.80 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more